TY - JOUR
T1 - Estimating the lifespan of elderly patients with cerebral metastases from kidney cancer
AU - Rades, Dirk
AU - Nguyen, Trang
AU - Schild, Steven E.
N1 - Publisher Copyright:
© 2020 International Institute of Anticancer Research. All rights reserved.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/6
Y1 - 2020/6
N2 - Background/Aim: Outcomes of elderly patients with cerebral metastases from kidney cancer may be improved by personalized treatment. A scoring instrument for estimating survival in these patients is presented. Patients and Methods: Twenty-four elderly kidney cancer patients receiving whole-brain irradiation (WBI) were retrospectively investigated. WBI-regimen and six pre-treatment factors were evaluated including age, gender, performance score, number of cerebral metastases, extracranial metastases and time from kidney cancer diagnosis to WBI. Results: Number of cerebral metastases (p=0.194) and time from kidney cancer diagnosis to WBI (p=0.107) correlated with survival and were included in the instrument. Based on these factors, patient scores of 0, 1 and 2 points resulted in 6-month survival rates of 0%, 15% and 60% (p=0.131), respectively. Two groups were designed, 0-1 and 2 points, with 6-month survival rates of 11% and 60% (p=0.108), respectively. Conclusion: This new instrument can assist physicians aiming to estimate a patient's survival prognosis to provide personalized treatment.
AB - Background/Aim: Outcomes of elderly patients with cerebral metastases from kidney cancer may be improved by personalized treatment. A scoring instrument for estimating survival in these patients is presented. Patients and Methods: Twenty-four elderly kidney cancer patients receiving whole-brain irradiation (WBI) were retrospectively investigated. WBI-regimen and six pre-treatment factors were evaluated including age, gender, performance score, number of cerebral metastases, extracranial metastases and time from kidney cancer diagnosis to WBI. Results: Number of cerebral metastases (p=0.194) and time from kidney cancer diagnosis to WBI (p=0.107) correlated with survival and were included in the instrument. Based on these factors, patient scores of 0, 1 and 2 points resulted in 6-month survival rates of 0%, 15% and 60% (p=0.131), respectively. Two groups were designed, 0-1 and 2 points, with 6-month survival rates of 11% and 60% (p=0.108), respectively. Conclusion: This new instrument can assist physicians aiming to estimate a patient's survival prognosis to provide personalized treatment.
UR - http://www.scopus.com/inward/record.url?scp=85084891865&partnerID=8YFLogxK
U2 - 10.21873/invivo.11908
DO - 10.21873/invivo.11908
M3 - Journal articles
C2 - 32354925
AN - SCOPUS:85084891865
VL - 34
SP - 1321
EP - 1324
JO - In Vivo
JF - In Vivo
SN - 0258-851X
IS - 3
ER -
